Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

被引：3

作者：

Russo, Filomena ^{[1
]}

Galluzzo, Marco ^{[2
,3
]}

Stingeni, Luca ^{[4
]}

Persechino, Severino ^{[5
]}

Zichichi, Leonardo ^{[6
]}

Conti, Andrea ^{[7
]}

Giofre, Claudia ^{[8
]}

Dini, Valentina ^{[9
]}

Vispi, Martina ^{[1
,10
]}

Atzori, Laura ^{[1
,11
]}

Cattaneo, Angelo ^{[1
,2
,12
]}

Parodi, Aurora ^{[1
,3
,13
]}

Bardazzi, Federico ^{[1
,4
,14
]}

Stinco, Giuseppe ^{[1
,5
,15
]}

Dapavo, Paolo ^{[1
,6
,16
]}

Girolomoni, Giampiero ^{[1
,7
,17
]}

Musumeci, Maria Letizia ^{[1
,8
,18
]}

Papini, Manuela ^{[1
,9
,19
]}

Venturini, Marina ^{[2
,20
]}

Dastoli, Stefano ^{[21
]}

Di Nuzzo, Sergio ^{[22
]}

Fargnoli, Maria Concetta ^{[23
]}

Pagnanelli, Gianluca ^{[24
]}

Bernardini, Nicoletta ^{[25
]}

Gambini, Daniele Mario ^{[26
]}

Malagoli, Piergiorgio ^{[27
]}

Mazzatenta, Carlo ^{[28
]}

Peris, Ketty ^{[29
]}

Zalaudek, Iris ^{[30
]}

Fabbrocini, Gabriella ^{[31
]}

Loconsole, Francesco ^{[32
]}

Vassallo, Camilla ^{[33
,34
]}

Pietroleonardo, Lucia ^{[35
]}

Prignano, Francesca ^{[36
]}

Franchi, Chiara ^{[37
]}

Offidani, Anna Maria ^{[38
]}

Bonifati, Claudio ^{[39
]}

Di Lernia, Vito ^{[40
]}

Gigante, Giovanni

Bartezaghi, Marta Silvia ^{[41
]}

Franchi, Matteo ^{[42
,43
]}

Ursoleo, Paola ^{[41
]}

Aloisi, Elisabetta ^{[41
]}

机构：

[1] Univ Siena, S Maria Alle Scotte Hosp, Dept Med Surg & Neurol Sci, Dermatol Sect, Siena, Italy

[2] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy

[3] Fdn Policlin Tor Vergata, Dermatol Unit, Rome, Italy

[4] Univ Perugia, Dept Med & Surg, Sect Dermatol, Perugia, Italy

[5] Sapienza Univ Rome, St Andrea Univ Hosp, Fac Med & Psychol, NESMOS Dept,Dermatol Unit, Rome, Italy

[6] San Antonio Abate Hosp, Unit Dermatol, Trapani, Italy

[7] Univ Modena & Reggio Emilia, Dept Specialized Med, Dermatol Sect, Modena, Italy

[8] AO Papardo, UOC Dermatol, Messina, Italy

[9] Univ Pisa, Dept Med & Oncol, Dermatol Sect, Pisa, Italy

[10] Misericordia Hosp, Dermatol Unit, Grosseto, Italy

[11] Univ Cagliari, Dept Med Sci & Publ Hlth, Dermatol Unit, Cagliari, Italy

[12] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[13] Univ Genoa, Osped Policlin San Martino IRCCS, Sect Dermatol, DiSSal, Genoa, Italy

[14] Univ Bologna, Dept Expt Diagnost & Specialty Med, Div Dermatol, Bologna, Italy

[15] Univ Udine, Dept Med, Dermatol Sect, Udine, Italy

[16] Univ Turin, Dept Med Sci, Sect Dermatol, Turin, Italy

[17] Univ Verona, Dept Med, Sect Dermatol, Verona, Italy

[18] Univ Catania, Dept Med & Surg Specialties, Sect Dermatol, Catania, Italy

[19] Univ Perugia, Dermatol Clin Terni, Perugia, Italy

[20] Univ Brescia, Dept Clin & Expt Sci, Sect Dermatol, Brescia, Italy

[21] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy

[22] Univ Parma, Dept Med & Surg, Parma, Italy

[23] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Dermatol Sect, Laquila, Italy

[24] Ist Dermopat Immacolata IRCCS, Dept Dermatol, Rome, Italy

[25] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Dermatol Unit Daniele Innocenzi, Asl Latina, Italy

[26] ASST Papa Giovanni XXIII Hosp, Dermatol Unit, Bergamo, Italy

[27] Azienda Osped San Donato Milanese, Dermatol Unit, Milan, Italy

[28] Lucca Azienda USL Toscana Nord Ovest, Dermatol Unit, Lucca, Italy

[29] Sacred Heart Catholic Univ, IRCCS A Gemelli Univ Polyclin Fdn, Dept Translat Med & Surg, Rome, Italy

[30] Univ Trieste, Dept Dermatol, Trieste, Italy

[31] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[32] Univ Bari, Dept Dermatol, Bari, Italy

[33] IRCCS Policlin San Matteo Fdn, Inst Dermatol, Pavia, Italy

[34] Univ Pavia, Pavia, Italy

[35] Vito Fazzi Hosp, Dermatol Unit, Lecce, Italy

[36] Univ Florence, Dept Hlth Sci, Dermatol Clin, Florence, Italy

[37] IRCCS IO Galeazzi, Dermatol Unit, Milan, Italy

[38] Polytech Univ Marche Reg, Dermatol Clin, Ancona, Italy

[39] IRCCS, Ist Dermatol San Gallicano, Dept Dermatol, Rome, Italy

[40] Arcispedale S Maria Nuova IRCCS, Dermatol Unit, Reggio Emilia, Italy

[41] Novartis Farma SpA, Origgio, Italy

[42] Natl Ctr Healthcare Res & Pharmacoepidemiol, Milan, Italy

[43] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Lab Healthcare Res & Pharmacoepidemiol, Milan, Italy

来源：

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY | 2023年 / 16卷

关键词：

psoriasis; secukinumab; real -world evidence; drug survival; SUPREME; HLA-CW6; STATUS; USTEKINUMAB;

D O I：

10.2147/CCID.S416149

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Purpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks.Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts.Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naive cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6-positive and HLA-Cw6-negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naive and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naive and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6-positive and HLA-Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings. Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.

引用

页码：3561 / 3574

页数：14

共 28 条

[1]

Alwan W, 2015, CLIN EXP RHEUMATOL, V33, pS2

[2] Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study) [J].

Bissonnette, R. ;

Luger, T. ;

Thaci, D. ;

Toth, D. ;

Lacombe, A. ;

Xia, S. ;

Mazur, R. ;

Patekar, M. ;

Charef, P. ;

Milutinovic, M. ;

Leonardi, C. ;

Mrowietz, U. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) :1507-1514

[3] The HLA-Cw6 Dilemma: Is It Really an Outcome Predictor in Psoriasis Patients under Biologic Therapy? A Monocentric Retrospective Analysis [J].

Burlando, Martina ;

Russo, Roberto ;

Clapasson, Andrea ;

Carmisciano, Luca ;

Stecca, Anna ;

Cozzani, Emanuele ;

Parodi, Aurora .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) :1-7

[4] Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study [J].

Chatzimichail, Giannis ;

Guenther, Julia ;

Staender, Sascha ;

Thaci, Diamant .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) :1749-1753

[5] Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study [J].

Costanzo, A. ;

Bianchi, L. ;

Flori, M. L. ;

Malara, G. ;

Stingeni, L. ;

Bartezaghi, M. ;

Carraro, L. ;

Castellino, G. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (05) :1072-1080

[6] NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis [J].

Coto-Segura, Pablo ;

Gonzalez-Lara, Leire ;

Batalla, Ana ;

Eiris, Noemi ;

Queiro, Ruben ;

Coto, Eliecer .

MOLECULAR DIAGNOSIS & THERAPY, 2019, 23 (05) :627-633

[7] HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis [J].

Dand, Nick ;

Duckworth, Michael ;

Baudry, David ;

Russell, Alice ;

Curtis, Charles J. ;

Lee, Sang Hyuck ;

Evans, Ian ;

Mason, Kayleigh J. ;

Alsharqi, Ali ;

Becher, Gabrielle ;

Burden, A. David ;

Goodwin, Richard G. ;

McKenna, Kevin ;

Murphy, Ruth ;

Perera, Gayathri K. ;

Rotarescu, Radu ;

Wahie, Shyamal ;

Wright, Andrew ;

Reynolds, Nick J. ;

Warren, Richard B. ;

Griffiths, Christopher E. M. ;

Smith, Catherine H. ;

Simpson, Michael A. ;

Barker, Jonathan N. ;

Benham, Marilyn ;

Hussain, Sagair ;

Kirby, Brian ;

Lawson, Linda ;

McElhone, Kathleen ;

Ormerod, Anthony ;

Owen, Caroline ;

Barnes, Michael R. ;

Di Meglio, Paola ;

Emsley, Richard ;

Evans, Andrea ;

Payne, Katherine ;

Stocken, Deborah ;

Barker, Jonathan ;

Burden, David ;

Griffiths, Christopher ;

Mason, Kayleigh ;

Reynolds, Nick ;

Smith, Catherine ;

Warren, Richard .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (06) :2120-2130

[8] Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis [J].

Egeberg, A. ;

Ottosen, M. B. ;

Gniadecki, R. ;

Broesby-Olsen, S. ;

Dam, T. N. ;

Bryld, L. E. ;

Rasmussen, M. K. ;

Skov, L. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) :509-519

[9] HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features [J].

Gudjónsson, JE ;

Kárason, A ;

Antonsdóttir, AA ;

Rúnarsdóttir, EH ;

Gulcher, JR ;

Stefánsson, K ;

Valdimarsson, H .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 118 (02) :362-365

[10] Psoriasis pathophysiology: current concepts of pathogenesis [J].

Krueger, JG ;

Bowcock, A .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 :30-36

← 1 2 3 →